Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Lipum AB Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.	Sweden	LIPUM
Liquidia Corp Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.	United States of America	LQDA
LISATA THERAPEUTICS, INC. Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.	United States of America	LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.	United States of America	LIXT
Longeveron Inc. Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.	United States of America	LGVN
Lonza Group AG A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.	Switzerland	LONN
Lyell Immunopharma, Inc. Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.	United States of America	LYEL
Lyra Therapeutics, Inc. Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).	United States of America	LYRA
Lytix Biopharma AS Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.	Norway	LYTIX
MaaT Pharma Developing gut microbiome therapies to improve survival for cancer patients.	France	MAAT